SABS
SAB Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.72
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 1.3M | 2.2M | 23.9M |
| Cost of Revenue | 2.3M | 3.1M | 4.8M | 3.7M | 3.3M |
| Gross Profit | (2.3M) | (3.1M) | (3.5M) | (1.5M) | 20.6M |
| Operating Expenses | |||||
| R&D Expense | 49.2M | 34.4M | 30.2M | 16.5M | 36.4M |
| SG&A Expense | 21.8M | 14.6M | 9.3M | 23.8M | 16.4M |
| General & Admin Expense | 22.6M | 14.6M | — | 23.8M | 16.4M |
| Selling & Marketing Expense | (731.0K) | — | — | — | — |
| Other Expenses | (1.5M) | (3.1M) | — | (3.7M) | (3.3M) |
| Total Operating Expenses | 69.5M | 45.9M | 39.4M | 36.6M | 49.5M |
| Cost and Expenses | 71.8M | 49.0M | 44.2M | 40.3M | 52.8M |
| Operating Income (EBIT) | (71.8M) | (49.0M) | (42.9M) | (38.1M) | (28.9M) |
| Non-Operating | |||||
| Interest Income | 4.1M | 1.4M | 1.3M | 585.0K | 71.1K |
| Interest Expense | 231.5K | 240.7K | 318.4K | 315.3K | 301.6K |
| Net Interest Income | 3.9M | 1.2M | 967.6K | 269.7K | (231.0K) |
| Other Non-Op Income/Expense | 59.0M | 62.2M | 8.8M | (4.1M) | 10.2M |
| Non-Operating Income (excl Interest) | (59.3M) | (62.5M) | (9.1M) | 3.8M | (10.5M) |
| EBT (Pre-Tax Income) | (12.8M) | 13.3M | (34.1M) | (42.2M) | (18.7M) |
| Income Tax Expense | — | — | — | — | 25.6K |
| Bottom Line | |||||
| Net Income | (12.8M) | 13.3M | (34.1M) | (42.2M) | (18.7M) |
| Earnings from Cont. Ops | (12.8M) | 13.3M | (34.1M) | (42.2M) | (18.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (74.8M) | (48.7M) | (34.1M) | (42.2M) | (18.7M) |
| Per Share | |||||
| Basic EPS | $3.57 | $0.22 | ($3.68) | ($7.64) | ($4.31) |
| Diluted EPS | ($0.86) | ($0.79) | ($3.68) | ($7.64) | ($4.31) |
| Revenue Per Share | $0.00 | $0.00 | $0.14 | $0.41 | $5.49 |
| Shares | |||||
| Basic Shares Outstanding | 79.8M | 19.3M | 9.3M | 5.5M | 4.4M |
| Diluted Shares Outstanding | 79.8M | 61.3M | 9.3M | 5.5M | 4.4M |
| Profitability Metrics | |||||
| EBITDA | (9.5M) | 16.6M | (29.0M) | (38.1M) | (15.1M) |
| D&A | 3.1M | 3.1M | 4.8M | 3.7M | 3.3M |
| EBIT | (12.5M) | 13.5M | (33.8M) | (41.9M) | (18.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026